Mariane Minussi Baptistella

Mrs. Mariane Minussi Baptistella

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
MBMariane Minussi Baptistella
Mariane Minussi Baptistella
ASAléxia Polo Siqueira
Aléxia Polo Siqueira
DMDâmaris Lizia Santos Magalhães
Dâmaris Lizia Santos Magalhães
BZBruno Zavan
Bruno Zavan
COCarolina Oliveira
Carolina Oliveira
Pollyanna Francielli de OliveiraPollyanna Francielli de Oliveira
Pollyanna Francielli de Oliveira
Colorectal cancer (CRC) therapy frequently relies on chemotherapeutic agents with high cytotoxicity, low selectivity, and suboptimal efficacy. Thus, the search for alternative therapeutic strategies for CRC continues. In the present work, the antitumor potential of a hybrid compound, which contains fragments derived from resveratrol and curcumin, was evaluated. These natural compounds are known by their antioxidant, chemopreventive, and chemotherapeutic properties. Different methodologic approaches were used to investigate cytotoxic, genotoxic, antiproliferative, and antioxidant effects of a hybrid compound, named PQM-162, on HCT-8 colorectal cancer cells. The results showed that PQM-162 displays radical scavenging capacity as demonstrated by DPPH assay. Furthermore, this substance reduced cell viability and inhibited cell cycle progression at G2/M in HCT-8 cells. Antiproliferative activity of PQM-162 was associated with its ability to modulate the expression of critical regulators of G2/M transition and mitosis progression such as PLK1, AURKB, and CDKN1A. Taken together, our data indicate that PQM-162 is a promising antitumor agent due to its disruption of the redox balance in cancer cells and its modulation of the expression of regulators of the cell cycle and mitotic apparatus.

15 July 2025 in Food Bioscience
Verified
Journal Article
Closed access
MCMichele Oliveira Carvalho
Michele Oliveira Carvalho
BMBruna Pereira Marquezini
Bruna Pereira Marquezini
LMLetícia Misuraca Meirelles
Letícia Misuraca Meirelles
COCarolina Oliveira
Carolina Oliveira
MBMariane Minussi Baptistella
Mariane Minussi Baptistella
Pollyanna Francielli de OliveiraPollyanna Francielli de Oliveira
Pollyanna Francielli de Oliveira

3 July 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
MBMariane Minussi Baptistella
Mariane Minussi Baptistella
COCarolina Oliveira
Carolina Oliveira
RARaphaela Rebeca Silveira Assunção
Raphaela Rebeca Silveira Assunção
Pollyanna Francielli de OliveiraPollyanna Francielli de Oliveira
Pollyanna Francielli de Oliveira
O câncer representa um dos maiores problemas de saúde pública do mundo. Apesar dos avanços crescentes e de alguns sucessos ocasionais, pacientes e profissionais da saúde permanecem enfrentando diversos contratempos procedentes da terapia oncológica. Nesse sentido, a quimioprevenção é interessante, pois implica evitar o sofrimento causado pelo câncer, tendo potencial efeito antes do diagnóstico, no prognóstico e, também, no tratamento. Nesta revisão, teve-se como objetivo elencar as principais abordagens quimiopreventivas, a nível primário, secundário e terciário, para os tumores mais frequentes no Brasil e que possuem correlação com hábitos cotidianos adotados. Para isso, foi realizado um levantamento bibliográfico das publicações disponíveis nas bases da National Library of Medicine (NIH – PubMed) e Scholar Google dos últimos 20 anos. Utilizou-se os descritores: “chemoprevention”, “cancer chemoprevention” “non melanoma skin cancer”, “lung cancer”, “breast cancer”, e “colorectal cancer”. São notáveis os resultados obtidos por diversos estudos in vitro e in vivo, tal qual as histórias de sucesso clínico. Não obstante, os desafios ainda são muitos devido, sobretudo, às variáveis encontradas nas respostas individuais dos pacientes, as quais podem ser influenciadas por especificidades do quadro clínico, e entre outros fatores, como também as limitações de investimento e adesão. Futuras pesquisas e investimento em educação e conscientização do público em geral e de profissionais da saúde, a respeito dos benefícios por trás da quimioprevenção do câncer, possibilitariam a ampla aplicação da quimioprevenção e beneficiariam diversos âmbitos da saúde.

9 July 2026 in The Cerebellum
Verified
Journal Article
Open access
PDF file
JSJonas José da Silva
Jonas José da Silva
MFManuela Eduarda de França
Manuela Eduarda de França
AXAlcides Euzebio Tavares Xavier
Alcides Euzebio Tavares Xavier
MBMariane Minussi Baptistella
Mariane Minussi Baptistella
EPEduardo Afonso da Silva Pereira
Eduardo Afonso da Silva Pereira
CSCarlos Alberto Scrideli
Carlos Alberto Scrideli
Medulloblastoma (MB), the most common malignant pediatric brain tumor, is classified into four molecular groups: WNT, SHH, G3, and G4. G3 and G4 MBs are characterized by poor prognosis and high metastatic potential. Although USP2 (ubiquitin-specific peptidase 2) has been described as a prognostic biomarker and a promising therapeutic target in several cancer types, its role in the pathogenesis of G3 and G4 MBs remains unexplored. In this study, USP2 expression was investigated through in silico analyses, public datasets (GSE85217), and tumor samples from 54 pediatric MB patients. In addition, the effects of USP2 inhibition were evaluated in two G3/G4 MB cell lines (D283 Med and USP-13) using ML364, a selective USP2 inhibitor. USP2 was overexpressed in G3 and G4 MBs and was associated with metastasis and unfavorable clinical outcomes. Furthermore, ML364 treatment reduced USP2 protein expression level, as well as cell viability, migration, invasion, and colony-forming capacity in both cell lines. These findings indicate that USP2 is upregulated in pediatric G3 and G4 MBs and support its potential role as a biomarker of poor prognosis and a therapeutic target in these molecular subgroups.